Metagenomi, Inc. (MGX)

Market Cap	88.32M
Revenue (ttm)	55.08M
Net Income (ttm)	-73.95M
Shares Out	37.42M
EPS (ttm)	-3.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	368,351
Open	2.470
Previous Close	2.440
Day's Range	2.360 - 2.520
52-Week Range	1.610 - 12.500
Beta	n/a
Analysts	Strong Buy
Price Target	16.67 (+606.36%)
Earnings Date	Mar 4, 2025

About MGX

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 2024
• Employees: 236
• Stock Exchange: NASDAQ
• Ticker Symbol: MGX
• Website: https://www.metagenomi.co

Financial Performance

In 2023, Metagenomi's revenue was $44.76 million, an increase of 160.21% compared to the previous year's $17.20 million. Losses were -$68.26 million, 56.6% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 606.36% from the latest price.

Price Target

$16.67

(606.36% upside)

Analyst Consensus: Strong Buy